AstraZeneca

Atlanta, Georgia

OncologyantibodyPhase IIIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

2mo agoTrial registeredMay 19, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Oct 27, 2023
Oropharynx Cancer, Stage I · SUSPENDED · sponsor: Emory University · Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
ClinicalTrials.gov · NCT06254911 (opens the source filing in a new tab)
Trial
NA registered
Mar 4, 2021
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma · COMPLETED · sponsor: M.D. Anderson Cancer Center · Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
ClinicalTrials.gov · NCT04872413 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 19, 2020
Esophageal Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: AstraZeneca · Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
ClinicalTrials.gov · NCT04550260 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 1, 2019
Mantle Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
ClinicalTrials.gov · NCT03710772 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.53name similarity 100% · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
5mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
Feb 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE2 registered

NA registered

PHASE3 registered

PHASE2 registered